Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®

Core Insights - Personalis, Inc. has published the PREDICT-DNA study in the Journal of Clinical Oncology, highlighting advancements in ultrasensitive molecular residual disease testing for breast cancer [1] Company Overview - Personalis, Inc. is recognized as a leader in advanced genomics specifically for precision oncology, indicating its strong position in the healthcare sector focused on cancer treatment [1] Study Findings - The PREDICT-DNA study demonstrates that ultrasensitive ctDNA assessment can effectively evaluate and detect minimal residual disease in breast cancer patients, showcasing the potential of NeXT Personal technology [1]